(Q53326795)

English

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

scientific article published on 8 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Michael Hutchinson

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

object named as

Eva Havrdova

6

0 references

David H. Miller

3

object named as

David H Miller

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

author name string

Robert J Fox

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

J Theodore Phillips

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Mariko Kita

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

John O'Gorman

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Ray Zhang

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Mark Novas

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Vissia Viglietta

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Katherine T Dawson

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

publication date

8 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

260

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

2286-2296

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

https://scigraph.springernature.com/pub.10.1007/s00415-013-6968-1

0 references

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

New perspectives in the natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Clinical prognostic factors in multiple sclerosis: a natural history review

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Natural history of multiple sclerosis: early prognostic factors.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Natural history of multiple sclerosis: long-term prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Relapses in multiple sclerosis are age- and time-dependent

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6968-1

21 January 2018

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749293

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749293

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749293

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749293

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-013-6968-1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/23749293

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53326795&oldid=1525066313"